Apremilast vs Crisaborole — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Phosphodiesterase 4 Inhibitor

Apremilast

Brand: Otezla

First FDA approval: 2020-02-26

Phosphodiesterase 4 Inhibitor

Crisaborole

Brand: Eucrisa

First FDA approval: 2017-01-30

Lowest NADACAcquisition cost floor across all NDCs

$89.95Per unit

$10.68Per unit

Average NADACAcross all dosage forms and strengths

$93.18Up to $98.89

$11.67Up to $12.65

Generic manufacturersActive ANDA holders — FDA Orange Book

515 total ANDAs filed

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$1.68BFull year

$13.7MFull year

Part D claims (CY24)Total fills, all strengths

332K61K beneficiaries

16K8K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$5,047Per claim, all NDCs

$881Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

1472Substantial friction

227Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

5Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes5 manufacturers

NoBrand-only